CN110846277B - 一种永生化的小鼠小胶质细胞系B6Mi1及其建立方法和应用 - Google Patents
一种永生化的小鼠小胶质细胞系B6Mi1及其建立方法和应用 Download PDFInfo
- Publication number
- CN110846277B CN110846277B CN201911111304.4A CN201911111304A CN110846277B CN 110846277 B CN110846277 B CN 110846277B CN 201911111304 A CN201911111304 A CN 201911111304A CN 110846277 B CN110846277 B CN 110846277B
- Authority
- CN
- China
- Prior art keywords
- microglia
- cell
- b6mi1
- cells
- mouse
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 24
- 230000002025 microglial effect Effects 0.000 title claims abstract description 23
- 210000004027 cell Anatomy 0.000 claims abstract description 121
- 210000000274 microglia Anatomy 0.000 claims abstract description 92
- 230000022131 cell cycle Effects 0.000 claims abstract description 13
- 238000012258 culturing Methods 0.000 claims abstract description 13
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims abstract description 12
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims abstract description 12
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims abstract description 9
- 102100022338 Integrin alpha-M Human genes 0.000 claims abstract description 9
- 238000004321 preservation Methods 0.000 claims abstract 4
- 238000001514 detection method Methods 0.000 claims description 21
- 238000005406 washing Methods 0.000 claims description 18
- 241000894007 species Species 0.000 claims description 16
- 238000010186 staining Methods 0.000 claims description 14
- 239000006285 cell suspension Substances 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 230000029087 digestion Effects 0.000 claims description 9
- 238000007789 sealing Methods 0.000 claims description 8
- 108090000631 Trypsin Proteins 0.000 claims description 7
- 102000004142 Trypsin Human genes 0.000 claims description 7
- 239000003550 marker Substances 0.000 claims description 7
- 239000006228 supernatant Substances 0.000 claims description 7
- 239000012588 trypsin Substances 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 101150087323 COI gene Proteins 0.000 claims description 5
- 230000001605 fetal effect Effects 0.000 claims description 5
- 230000035755 proliferation Effects 0.000 claims description 5
- 238000012408 PCR amplification Methods 0.000 claims description 4
- 229930040373 Paraformaldehyde Natural products 0.000 claims description 4
- 238000005206 flow analysis Methods 0.000 claims description 4
- 238000010166 immunofluorescence Methods 0.000 claims description 4
- 229920002866 paraformaldehyde Polymers 0.000 claims description 4
- 102100030878 Cytochrome c oxidase subunit 1 Human genes 0.000 claims description 3
- 108090000365 Cytochrome-c oxidases Proteins 0.000 claims description 3
- 241000581650 Ivesia Species 0.000 claims description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 3
- 230000004071 biological effect Effects 0.000 claims description 2
- 238000004043 dyeing Methods 0.000 claims description 2
- 238000012744 immunostaining Methods 0.000 claims description 2
- 238000011534 incubation Methods 0.000 claims description 2
- 238000012758 nuclear staining Methods 0.000 claims description 2
- 239000012128 staining reagent Substances 0.000 claims description 2
- 239000002771 cell marker Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 238000010367 cloning Methods 0.000 abstract description 8
- 230000002757 inflammatory effect Effects 0.000 abstract description 7
- 238000000746 purification Methods 0.000 abstract description 7
- 208000036110 Neuroinflammatory disease Diseases 0.000 abstract description 6
- 230000003959 neuroinflammation Effects 0.000 abstract description 6
- 238000004458 analytical method Methods 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 4
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 abstract description 3
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 3
- 238000011160 research Methods 0.000 abstract description 3
- 102100040121 Allograft inflammatory factor 1 Human genes 0.000 abstract description 2
- 101000890626 Homo sapiens Allograft inflammatory factor 1 Proteins 0.000 abstract description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 abstract description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 abstract description 2
- 108090001005 Interleukin-6 Proteins 0.000 abstract description 2
- 102000004889 Interleukin-6 Human genes 0.000 abstract description 2
- 238000012216 screening Methods 0.000 abstract description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 27
- 210000001519 tissue Anatomy 0.000 description 20
- 239000000243 solution Substances 0.000 description 18
- 241000700159 Rattus Species 0.000 description 15
- 238000010586 diagram Methods 0.000 description 12
- 239000002158 endotoxin Substances 0.000 description 10
- 229920006008 lipopolysaccharide Polymers 0.000 description 10
- 210000003169 central nervous system Anatomy 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 5
- 210000005013 brain tissue Anatomy 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 238000002224 dissection Methods 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 238000012650 click reaction Methods 0.000 description 4
- 238000010874 in vitro model Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000001994 activation Methods 0.000 description 3
- 238000010009 beating Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 210000001642 activated microglia Anatomy 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000001130 astrocyte Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 210000005056 cell body Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 238000003113 dilution method Methods 0.000 description 2
- 238000007877 drug screening Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000006862 enzymatic digestion Effects 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 230000035519 G0 Phase Effects 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 230000004668 G2/M phase Effects 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101150101999 IL6 gene Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 206010021888 Nervous system infections Diseases 0.000 description 1
- 101150101537 Olah gene Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108010022439 Oncogene Proteins v-raf Proteins 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 101710101493 Viral myc transforming protein Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 210000004713 immature microglia Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000006724 microglial activation Effects 0.000 description 1
- 230000006756 microglial proliferation Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- -1 v-raf Proteins 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/30—Synthetic polymers
- C12N2533/32—Polylysine, polyornithine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dispersion Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明提供一种永生化的小鼠小胶质细胞系B6Mi1,在中国典型培养物保藏中心(CCTCC)的保藏编号为CCTCC NO:C2019263,保藏日期为2019年11月6日。小鼠小胶质细胞系的建立方法包括如下步骤:a、原代小鼠小胶质细胞的分离和培养;b、原代小鼠小胶质细胞的纯化和克隆。本发明的小鼠小胶质细胞为自发永生化的小胶质细胞,IBA1阳性,CD45+CD11b+。B6Mi1细胞增殖旺盛,细胞周期分析显示超过一半的细胞处于S期和G2M期,细胞倍增时间为14小时。LPS处理可以显著增加该细胞表达TNFα,IL‑1β、IL‑6、iNOS等炎症因子。上述结果表明B6Mi1细胞为具有microglia细胞表型和生物学特性的小鼠小胶质细胞系,该细胞系可以用于小胶质细胞生物学特性及神经炎症的研究及相关药物的筛选和开发。
Description
技术领域
本发明属于细胞生物学领域,具体涉及一种永生化的小鼠小胶质细胞系B6Mi1及其建立方法和应用。
背景技术
小胶质细胞是中枢神经系统(CNS)的主要胶质细胞,约占哺乳动物大脑细胞总数的12%。小胶质细胞起源于髓系,是定居在CNS中的免疫细胞,在维持CNS内环境的稳定和重建中发挥重要作用。当CNS微环境发生变化时,小胶质细胞被激活,在包括神经退行性疾病、创伤性脑损伤和神经系统感染等多种损伤和疾病中都可以发现活化小胶质细胞的存在。激活的小胶质细胞增殖、形态发生改变,吞噬活性增强,产生大量的活性氧和活性氮,分泌促炎趋化因子和细胞因子。小胶质细胞通过产生生长因子和清除潜在的毒性细胞碎片来提高神经元的生存能力和存活率,但也有证据表明,激活的小胶质细胞通过过度产生炎症介质而损伤神经元。在神经退行性疾病中,小胶质细胞及其分泌是促进神经元死亡的主要因素。因此,了解小胶质细胞的分泌和调节小胶质细胞激活的机制是制定改善这些疾病症状的治疗策略的重要一步。培养的小胶质细胞是认识和研究其生物学功能的重要工具,也是研究多种中枢神经系统(CNS)疾病中炎症相关机制以及探讨靶向小胶质细胞治疗策略的一种重要的体外模型。
由于脑中细胞的高度异质性,很难直接获得小胶质细胞,需要通过原代培养的方法才能获得一定数量具有较好活性和较高纯度的小胶质细胞用于小胶质细胞的神经保护和神经毒性作用的研究。目前已建立了分离培养小鼠、大鼠、非人类灵长类动物和人类原代小胶质细胞的方法。这些方法通常都是采用机械和酶解相结合的方法将脑组织分散为单个细胞,混合培养后采用摇晃或者敲打的方式纯化出小胶质细胞(Tamashiro et al.,2012)。或在酶解后,通过密度梯度离心将小胶质细胞从含着大量髓鞘成分的酶解混合物中分离出来,然后通过磁珠分选(Nikodemova and Watters,2012;Mizee等,2017)或荧光标记结合流式分选(FACS)的方法直接分离出小胶质细胞(Olah等,2012)。由于便于操作且不要特殊仪器设备,混合原代培养最为常用。上述分离培养的时间通常包括6h解剖组织和接种细胞,随后2-3周的培养,以及最后的纯化和接种时间,通常需要6h。对于大鼠,每个脑能够获得的2.7*104~1*106的小胶质细胞。如果需要增加细胞的产量,则需要增加起始的幼崽数量。
尽管原代培养小胶质细胞的技术已十分成熟,但该过程繁琐、耗时长且结果不稳定,且原代培养的小胶质细胞通常不能够传代培养。相比之下,细胞系具有无限的增殖能力,具有易于维护和便于使用的优点,因而常替代原代小胶质细胞用于实验研究。目前已有小鼠、大鼠、猕猴和人类起源的小胶质细胞系,这些细胞系大多通过将病毒与癌基因(如v-myc、v-raf、v-mil、SV40 T抗原)转入到培养的大脑或脊髓的原代小胶质细胞以实现永生化。也有从原代培养小胶质细胞自发永生化的报道。
发明内容
本发明要解决的技术问题是提供一种永生化的小鼠小胶质细胞系及其建立方法和应用,细胞系保持了小胶质细胞的特性,为研究小胶质细胞的生物特性、神经炎症和药物筛选提供了一个良好的体外模型。
为解决上述技术问题,本发明的实施例提供一种永生化的小鼠小胶质细胞系B6Mi1。
本发明还提供一种永生化的小鼠小胶质细胞系B6Mi1的建立方法,包括如下步骤:
a、原代大鼠小胶质细胞的分离和培养
无菌分离P0小鼠的大脑皮层,剪切为1mm3的组织块,PBS清洗多次后,加入0.125%胰酶,37℃消化10min,终止后吹打成混合细胞悬液,100μm筛网过滤后接种到多聚赖氨酸包被的培养瓶,37℃、5%CO2饱和湿度培养,每日观察并根据培养基的消耗情况半量换液;
b、原代大鼠小胶质细胞的纯化和克隆
混合细胞培养至2~3周,采用手工敲打法纯化原代小胶质细胞,待小胶质细胞脱落后,将细胞悬液转移至15ml离心管,300g室温离心5min,离心结束后用含10%胎牛血清的DEME培养基重悬后计数接种;通过有限稀释法进行克隆实验。
本发明还提供一种永生化的小鼠小胶质细胞系B6Mi1的检测方法,步骤b中随机选择其中一个克隆命名为B6Mi1;所述检测方法包括如下步骤:
(1)B6Mi1小胶质细胞标志物检测
(1-1)小胶质细胞标志物IBA-1的免疫荧光检测:对于培养好的小胶质细胞,加入预冷的4%的多聚甲醛室温下固定20min;固定结束后免疫染色封闭液室温下封闭1h;使用一抗IBA-1过夜染色,隔天二抗、染核试剂Hochest染色孵育后进行封片,于荧光显微镜下观察拍照;
(1-2)小胶质细胞表面标志物的流式分析:将培养好的B6Mi1/BV2细胞用0.125%胰蛋白酶消化后离心,1%BSA重悬细胞清洗一次后用小胶质细胞表面分子CD45和CD11b染色,放置冰上避光孵育1h后上机检测。
(2)B6Mi1的细胞倍增时间与细胞周期
(2-1)根据细胞倍增时间公式:DT=t×[lg2/(lgNt-lgN0)],计算得B6小胶质细胞倍增时间为13.25h;
其中,t为培养时间,Nt为t时间后的细胞数,N0为接种细胞数;
(2-2)采用EdU检测细胞的增殖活性:将培养的原代大鼠小胶质细胞以1×105cell/孔接种于24孔板中,培养24h后加入终浓度为10μEdU继续培养4h,固定、染色;
(2-3)采用PI染色检测细胞周期:将1.5*105B6Mi1接种于12孔板,培养至8h,加入300μl 0.125%胰蛋白酶消化细胞,加入30μl FBS终止消化,轻轻吹散至单细胞悬液;逐滴加入预冷的7000μl无水乙醇,期间轻轻晃动培养板,将细胞悬液转移至流式管,置于冰上固定10min;加入1ml预冷的PBS,400g离心5min,倒扣弃上清;加入300μl预冷的含有PI染料的PBS,轻弹管壁重悬细胞,染色15min后流式检测细胞周期;
(3)B6Mi1小胶质细胞物种鉴定:根据细胞色素C氧化酶基因COI在不同的物种间存在物种差异进行物种鉴定。提取SD大鼠胎鼠皮层组织、C57/BL6小鼠尾尖和B6Mi1小胶质细胞基因组DNA,通过PCR扩增COI基因,琼脂糖凝胶电泳检测PCR扩增产物确定。
本发明还提供一种体外模型,所述体外模型为利用如权利要求2所述的建立方法建立的可以在体外长期培养并保持小胶质细胞特性的小胶质细胞系。
本发明还提供了永生化的小鼠小胶质细胞系B6Mi1的检测方法在制备神经炎症药物方面的用途、在小胶质细胞生物学特性研究方面的用途。
本发明通过有限稀释法获得12个克隆,随机选择一个命名为B6Mi1,目前已传超过40代。于2019年11月6日保藏在中国典型培养物保藏中心(CCTCC),地址:湖北省武汉市武昌区武汉大学保藏中心(武汉大学第一附属小学对面),邮编:430072,保藏编号:CCTCC NO:C2019263。
本发明的上述技术方案的有益效果如下:
本发明提供了一种小鼠小胶质细胞系及其建立方法和应用,为自发永生化的小胶质细胞,呈IBA1阳性,CD45+CD11b+。B6Mi1细胞增殖旺盛,细胞周期分析显示超过一半的细胞处于S期和G2M期,细胞倍增时间为14小时。LPS处理可以显著增加该细胞表达TNFα,IL-1β、IL-6、iNOS等炎症因子。上述结果表明B6Mi1细胞为具有microglia细胞表型和生物学特性的小鼠小胶质细胞系,该细胞系可以用于小胶质细胞生物学特性及神经炎症的研究及相关的药物筛选和开发。
附图说明
图1为本发明中C57/BL6小鼠鼠原代细胞混合培养至5天、10天和15天时的示意图;
图2为本发明中纯化后的C57/BL6小鼠原代小胶质细胞形态和克隆实验结果示意图;
图3为本发明中小胶质细胞系B6Mi1标志物IBA-1的免疫荧光检测结果示意图;
图4为本发明中B6Mi1小胶质细胞的细胞表面分子的流式检测结果示意图;
图5为本发明中B6Mi1小胶质细胞物种鉴定的检测结果示意图;
图6为本发明中B6Mi1小胶质细胞增殖和细胞周期的分析结果示意图;
图7为本发明中LPS处理改变了B6Mi1细胞的形态并诱导炎症因子的转录示意图。
具体实施方式
为使本发明要解决的技术问题、技术方案和优点更加清楚,下面将结合附图及具体实施例进行详细描述。
实施例1
本实施例提供了一种永生化的小鼠小胶质细胞系B6Mi1的建立方法,包括如下步骤:
a、原代小鼠小胶质细胞的分离和培养
准备工作:
预先包被培养瓶:细胞培养瓶(底面积为75cm2)中加入5ml多聚-D-氨酸(0.1mg/mL),保鲜袋包裹好后放置在4℃冰箱包被过夜,隔天用灭菌的Mini Q水清洗三次,于超净工作台紫外风干后备用。
解剖新生鼠脑组织:
1.取材过程全程在冰上操作,最大限度保持细胞活性。取3只C57/BL6小鼠,用酒精棉球将小鼠全身擦拭干净,再置于75%酒精浸泡1min后擦拭干净。手术剪剪断头置于盛有6ml预冷解剖液(庆大霉素用PBS稀释成400单位)的60mm培养皿中清洗,将组织转移至新的盛有6ml预冷解剖液的培养皿中清洗,再重复清洗两次直至没有血丝。
2.眼科直镊固定双眼,眼科弯镊沿着脑部中线撕取头皮以及软骨盖,暴露出整个脑部,更换新的显微镊小心去除全脑组织取出放置盛有3ml预冷解剖液的培养皿中,剩余组织同样操作。
3.在体视显微镜下进行精细操作,沿着大脑半球中线将皮层翻开,分离出两侧皮层,去除血管膜,海马组织后放置盛有3ml解剖液的60mm细胞培养皿中,剩余组织同样操作。
混合胶质细胞培养:
1.解剖完毕后,用1ml的枪头将组织吸入再转移至15ml离心管,待组织沉降管底后,弃取上清;加入4ml预冷PBS清洗组织,待组织沉降管底后,弃上清;重复清洗一次。
2.加入预热的6ml消化液(0.25%胰蛋白酶用PBS稀释1倍使用),放置培养箱中(37℃、5%CO2)消化10min,期间每隔5min轻弹管壁以充分消化。
3.消化结束后,弃去消化液,加入4ml预冷的PBS终止消化,待组织沉降管底后弃上清;重复1次。
4.将100μm滤器放置在50ml离心管上,加入1ml PBS充分浸润。在组织中加入4ml预热的PBS,吹打15次,待组织沉降于管底后,吸取上清至滤器中,重复两次。
5.将细胞悬液以300g室温离心5min,加入3ml预热的完全培养基(DMEM/HIGHGLΜCOSE+10%胎牛血清)重悬细胞后接种至培养瓶,并补充培养基至8ml。
6.第二天将培养基弃去,添加10ml完全培养基,之后依据培养基的消耗情况(3-4天)补充新鲜的完全培养基。
培养至第10天,下层星形胶质细胞铺展成片状,小胶质细胞位于星形胶质细胞上层,细胞数量较少,胞体透亮,折光性较好,呈圆形,大小均一。培养至15天时,小胶质细胞数量显著增多并呈“簇状”生长,如图1所示为B6小鼠原代细胞混合培养5天至15天的示意图,比例尺分别为:200μm(左)、100μm(中)和50μm(右)。
b、原代小鼠小胶质细胞的纯化和克隆
混合细胞培养至2~3周,采用手工敲打法纯化原代小胶质细胞,待小胶质细胞大部分脱落后,将细胞悬液转移至15ml离心管,300g室温离心5min,离心结束后用含10%胎牛血清的DEME培养基重悬后计数接种。接种后贴壁的小胶质细胞胞体透亮,折光性较好,形态呈现圆形或梭形,部分从胞体伸出细长分支;培养至第2天,分支部分回缩,细胞变圆;培养至第3、4天细胞数量显著增多,细胞形态也转变为以圆形为主,如图2A(上行)所示为纯化后培养1-4天的B6小鼠原代小胶质细胞的形态。比例尺:100μm。
通过有限稀释法进行克隆形成实验,培养3天即可观察到克隆的形成,5天可形成巨大的细胞克隆。收集12个克隆,随机选择其中一个命名为B6Mi1,用于随后细胞生长和生物学特性的分析,该克隆多次传代后细胞的形态没有明显改变。如图2B(下行)所示为克隆实验,细胞接种后1天,5天和10天的克隆结果图。
实施例2
本实施例提供一种永生化的小鼠小胶质细胞系B6Mi1的检测方法,步骤b中随机选择其中一个克隆命名为B6Mi1;所述检测方法包括如下步骤:
(1)B6Mi1小胶质细胞标志物检测
(1-1)小胶质细胞标志物IBA-1的免疫荧光检测
取出培养好的小胶质细胞,吸除孔内的培养基,加入500μl PBS清洗1次;每孔加入预冷的4%的多聚甲醛500μl,室温下固定20min;吸除固定液,加入500μl PBS清洗3次,每次5min;每孔加入200μl免疫染色封闭液,室温下封闭1h;吸除封闭液,每个玻片上滴加200μl的一抗(IBA-1,1:200配置),置于湿盒内4℃过夜;第二天取出培养板,吸除一抗,PBS洗3次,每次5min;加入200μl荧光二抗,室温避光孵育1h;吸除二抗,PBS清洗3次,每次5min;每孔加入200μl DAPI(1μg/ml),室温避光孵育10min;吸除染核试剂,PBS清洗1次,5min;在载玻片上滴加7μl的仿淬灭荧光封片剂,取出玻片,细胞层面朝下放于滴加的封片剂上封片;荧光显微镜下观察拍照。
IBA-1是小胶质细胞典型标志物,免疫荧光染色显示,IBA-1阳性的细胞呈现“分支”状态,而多数圆形状小胶质细胞不表达IBA-1,如图3所示,IBA-1(1:250),Hochest(1μg/ml);比例尺:100μm(上),50μm(下)。
(1-2)小胶质细胞表面标志物的流式分析
将1.5*105B6Mi1/BV2细胞接种于12孔板,培养至8h;加入300μl 0.125%胰蛋白酶消化细胞,加入600μl含10%胎牛血清的DEME培养基终止消化,轻轻吹散至单细胞悬液,300g室温离心5min;加入2ml 1%BSA重悬细胞,平均分配到2个流式管中,再分别补充添加2ml BSA(扩大体积);500g室温离心5min,倒扣,管中保留100μl液体;其中一管加入0.5μlCD45和CD11b,放置冰上避光孵育1h后上机检测。
通过流式分析了CD45、CD11b在B6Mi1和BV2细胞的表达,结果显示100%的BV2和B6Mi1细胞都是CD45和CD11b阳性的。值得注意的是根据CD45的荧光强度,BV2和B6Mi细胞都可以分为两个细胞群:CD45highCD11b+和CD45lowCD11b+,这与缺血脑组织中的单核细胞的种模式类似,其中CD45high的是从外周募集的单核巨噬细胞,而CD45low的则是脑中固有的小胶质细胞,因此BV2和B6Mi1细胞似乎也具有两种不同的表型。并且与BV2细胞相比,B6Mi1细胞中CD45high的比例要高于BV2。如图4所示为B6Mi1小胶质细胞的细胞表面分子的流式检测结果示意图。
(2)B6Mi1的细胞倍增时间与细胞周期
(2-1)根据细胞倍增时间公式:DT=t×[lg2/(lgNt-lgN0)],计算得B6小胶质细胞(B6Mi)倍增时间为13.25h;
其中,t为培养时间,Nt为t时间后的细胞数,N0为接种细胞数;
(2-2)采用EdU检测细胞的增殖活性:将培养的原代小鼠小胶质细胞以5×104cell/孔接种于24孔板中,培养24h后加入终浓度为10μM EdU继续培养1h;培养结束,去除培养基,加入300μl4%多聚甲醛室温固定15min;1ml洗涤液(含3%BSA的PBS)清洗3次,每次3-5min;去除洗涤液,1ml通透液(含3%Triton*-100的PBS)室温孵育10-15min;洗涤液清洗细胞1-2次,每次3-5min;配制Click反应液,以下是每孔的量:
组分 | |
Click Reaction Bμffer | 86μl |
CμSO4 | 4μl |
Azide 555 | 0.2μl |
Click Additive Solμtion | 10μl |
总体积 | 100.2μl |
。
去除洗涤液,每孔加入100μl Click反应液,轻轻摇匀,均匀覆盖样品,室温避光孵育30min;吸除Click反应液,洗涤液清洗细胞3次,每次3-5min;Hochest 33342按1:1000稀释,加入到细胞中,室温避光孵育10min;清洗细胞3次,每次3-5min;滴加一滴抗荧光封片剂进行封片,荧光显微镜下拍照。。结果如图6所示,EdΜ阳性细胞数不低于95%,说明该小胶质细胞系具有较高的增殖活性。其中,图6A为Edμ掺入检测B6Mi1细胞增殖检测,EdU(10μM)标记1h,Hochest(1μg/ml),比例尺:100μm。图6B为B6Mi1细胞周期流式检测结果的ModFit软件拟合的结果示意图。
(2-3)采用PI染色检测细胞周期:将1.5*105B6Mi1接种于12孔板,培养至8h(进入对数生长期),加入300μl 0.125%胰蛋白酶消化细胞,加入30μl FBS终止消化,轻轻吹散至单细胞悬液;逐滴加入预冷的7000μl无水乙醇,期间轻轻晃动培养板,将细胞悬液转移至流式管,置于冰上固定10min;加入1ml预冷的PBS(扩大体积),400g离心5min,倒扣弃上清;加入300μl预冷的含有PI染料的PBS(PI储存液浓度为1mg/ml,终浓度为40μg/ml),轻弹管壁重悬细胞,染色15min后流式检测细胞周期。结果显示:处于G0/G1期的细胞占45%,S期的细胞占44%,G2/M期细胞大约占11%。
(3)小胶质细胞物种鉴定
基因组DNA小量抽提:取SD大鼠胎鼠皮层组织15mg、C57/BL6小鼠尾尖0.6cm,剪切成尽可能小的碎片,加入180μl样品裂解液A,20μl蛋白酶K涡旋5-10s混匀,55℃水浴孵育过夜直至完全裂解;将培养的原代小鼠小胶质细胞以8×105cell/孔接种于底面积为21cm2的培养皿,待细胞生长至70%左右,收集细胞(约300万左右细胞),消化离心后加入200μl PBS重悬细胞,加入20μl蛋白酶K涡旋5-10s混匀;大鼠胎鼠皮层组织、C57/BL6小鼠尾尖组织和原代小鼠小胶质细胞加入200μl样品裂解液后立即涡旋混匀,70℃金属浴孵育10min;加入200μl无水乙醇,涡旋5-10s混匀;将混合物转移至DNA纯化柱,8000g室温离心1min,弃去废液收集管内液体;加入500μl洗涤液1,8000g室温离心1min,弃去废液收集管内液体;加入600μl洗涤液2,17000g室温离心1min,弃去废液收集管内液体;17000g室温离心1min,去除残留的乙醇;将DNA纯化柱置于洁净的1.5ml离心管,加入50μl洗脱液,室温放置1min;17000g室温离心1min,所得液体即为纯化得到的总DNA,上机检测浓度。如图5所示为B6Mi1小胶质细胞物种鉴定的检测结果示意图。
PCR扩增体系依据下表:
PCR反应参数设置:
STEP1(起始变性):3min STEP2(变性):30sec STEP3(退火):30sec STEP4(延伸):1min STEP5(循环):Go To STEP2 for 30cycles STEP6(最终延伸):10min STEP7(临时保存):forever
细胞色素C氧化酶基因COI在不同的物种间存在物种差异,目前可作为物种鉴定的一种分子标记。依据该文献的物种COI基因序列扩增出大小鼠组织以及原代小鼠小胶质细胞COI基因。采用浓度为2%的琼脂糖凝胶电泳检测PCR扩增产物,条带单一清晰可见,大小鼠COI基因条带作为阳性对照,原代小胶质细胞COI基因条带如图所示,条带位置正确。
(4)LPS处理可显著增加B6Mi1细胞炎症因子的表达
在体小胶质细胞的激活表现为由呈现多分支(ramified)状的静息小胶质细胞的形态转变为阿米巴样。脂多糖(LPS)被用于模拟革兰氏阴性菌的感染和研究小胶质细胞的激活过程。1μg/ml LPS处理B6Mi1和BV2细胞6h,细胞的形态从球形转变为扁平的圆形,Tnfα、iNOS、Il-6和Il-1β的转录水平显著增加。LPS对B6Mi1和BV2细胞的作用类似,除了Il-6。如图7所示为LPS处理改变了B6Mi1细胞的形态并诱导炎症因子的转录示意图,其中图7A为LPS处理对B6Mi1细胞形态的影响示意图,图7B为LPS显著增加B6Mi1细胞中炎症因子的表达示意图。
引物序列:
实施例3
实施例2中的结果说明本发明的建立方法获得的小胶质细胞可以在体外长期培养并保持小胶质细胞的特性,为小胶质细胞的研究和神经炎症药物筛选提供了一个体外模型。
实施例4
本实施例的永生化的小鼠小胶质细胞系可用于制备神经炎症药物,也可用于小胶质细胞生物学特性研究方面。
以上所述是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明所述原理的前提下,还可以作出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (3)
1.一种永生化的小鼠小胶质细胞系B6Mi1,其特征在于,所述小鼠小胶质细胞系在中国典型培养物保藏中心的保藏编号为CCTCC NO:C2019263,保藏日期为2019年11月6日。
2.一种如权利要求1所述的永生化的小鼠小胶质细胞系B6Mi1的检测方法,其特征在于,所述检测方法包括如下步骤:
(1)B6Mi1小胶质细胞标志物检测
(1-1)小胶质细胞标志物IBA-1的免疫荧光检测:对于培养好的小胶质细胞,加入预冷的4%的多聚甲醛室温下固定20min;固定结束后免疫染色封闭液室温下封闭1h;使用一抗IBA-1过夜染色,隔天二抗、染核试剂Hochest染色孵育后进行封片,于荧光显微镜下观察拍照;
(1-2)小胶质细胞表面标志物的流式分析:将培养好的 B6Mi1/BV2细胞用 0.125%胰蛋白酶消化后离心,1%BSA重悬细胞清洗一次后用小胶质细胞表面分子CD45和CD11b染色,放置冰上避光孵育1h后上机检测;
(2)B6Mi1的细胞倍增时间与细胞周期
(2-1)根据细胞倍增时间公式:DT=t×[lg2/(lgNt-lgN0)],计算得B6小胶质细胞倍增时间为13.25h ;
其中,t为培养时间,Nt为t时间后的细胞数,N0为接种细胞数;
(2-2)采用EdΜ检测细胞的增殖活性:将培养的原代小鼠小胶质细胞以5*104cell/孔接种于24孔板中,培养24h后加入终浓度为10μM EdΜ继续培养1h,固定、染色;
(2-3)采用PI染色检测细胞周期:将1.5*105 B6Mi1接种于12孔板,培养至8h,加入300μl0.125%胰蛋白酶消化细胞,加入30μl FBS终止消化,轻轻吹散至单细胞悬液;逐滴加入预冷的700μl无水乙醇,期间轻轻晃动培养板,将细胞悬液转移至流式管,置于冰上固定10min;加入1ml预冷的PBS,400g离心5min,倒扣弃上清;加入300μl预冷的含有PI染料的PBS,轻弹管壁重悬细胞,染色15min后流式检测细胞周期;
(3)B6Mi1小胶质细胞物种鉴定:根据细胞色素C氧化酶基因COI在不同的物种间存在物种差异进行物种鉴定;提取SD大鼠胎鼠皮层组织、C57/BL6小鼠尾尖和B6Mi1小胶质细胞基因组DNA,通过PCR扩增COI基因,琼脂糖凝胶电泳检测PCR扩增产物确定。
3.权利要求1所述的永生化的小鼠小胶质细胞系B6Mi1或者权利要求2所述的永生化的小鼠小胶质细胞系B6Mi1的检测方法在小胶质细胞生物学特性研究方面的用途。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911111304.4A CN110846277B (zh) | 2019-11-14 | 2019-11-14 | 一种永生化的小鼠小胶质细胞系B6Mi1及其建立方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911111304.4A CN110846277B (zh) | 2019-11-14 | 2019-11-14 | 一种永生化的小鼠小胶质细胞系B6Mi1及其建立方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110846277A CN110846277A (zh) | 2020-02-28 |
CN110846277B true CN110846277B (zh) | 2023-01-13 |
Family
ID=69600276
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911111304.4A Active CN110846277B (zh) | 2019-11-14 | 2019-11-14 | 一种永生化的小鼠小胶质细胞系B6Mi1及其建立方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110846277B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111718999B (zh) * | 2020-06-03 | 2022-11-22 | 广州赛库生物技术有限公司 | 小鼠短串联重复序列的多重扩增体系及检测试剂盒 |
CN114426951B (zh) * | 2020-10-29 | 2024-05-14 | 北京赛尔湃腾科技咨询合伙企业(有限合伙) | 利用多能干细胞制备小胶质细胞样细胞的方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104513808A (zh) * | 2013-09-30 | 2015-04-15 | 复旦大学附属眼耳鼻喉科医院 | 一种视网膜高趋化性的大鼠视网膜小胶质细胞系 |
CN109609459A (zh) * | 2019-01-02 | 2019-04-12 | 温州医科大学 | 一种小胶质细胞的培养方法 |
-
2019
- 2019-11-14 CN CN201911111304.4A patent/CN110846277B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104513808A (zh) * | 2013-09-30 | 2015-04-15 | 复旦大学附属眼耳鼻喉科医院 | 一种视网膜高趋化性的大鼠视网膜小胶质细胞系 |
CN109609459A (zh) * | 2019-01-02 | 2019-04-12 | 温州医科大学 | 一种小胶质细胞的培养方法 |
Non-Patent Citations (2)
Title |
---|
An Immortalized Microglial Cell Line (Mocha) Derived From Rat Cochlea;G M Seigel等;《Mol Cell Neurosci.》;20171231;202–210 * |
新型人源永生化小胶质细胞系HM-SV40体外炎症反应模型的建立及优化研究;吴相枝;《中国优秀硕士论文全文数据库 医药卫生科技辑》;20190915;全文 * |
Also Published As
Publication number | Publication date |
---|---|
CN110846277A (zh) | 2020-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101821383B (zh) | 一种用于人成体原始间充质干细胞体外规模化培养的培养基、方法及获得的原始间充质干细胞及其应用 | |
CN104450611B (zh) | 一种人羊膜间充质干细胞原代分离及培养方法 | |
US11339372B2 (en) | Serum-free medium inducing differentiation of umbilical cord mesenchymal stem cell into insulin-secretion-like cell and preparation method and use thereof | |
CN105331575B (zh) | 一种人血管内皮祖细胞的高效扩增培养体系 | |
CN110846277B (zh) | 一种永生化的小鼠小胶质细胞系B6Mi1及其建立方法和应用 | |
CN108504625B (zh) | 一种小鼠成纤维细胞及其用途 | |
Liu et al. | Comparison of the biological characteristics of mesenchymal stem cells derived from bone marrow and skin | |
CN104762257B (zh) | 一种从脐带制备间充质干细胞的方法 | |
WO2018082316A1 (zh) | 千金藤碱的应用以及一种扩增造血干细胞的培养基和方法 | |
CN104774808B (zh) | 将脐带间充质干细胞诱导分化成γ-氨基丁酸能神经元的方法 | |
CN104694470A (zh) | 一种干细胞无血清培养基 | |
JP7098187B2 (ja) | 多能性幹細胞及びその分化したt細胞と使用 | |
CN104789531B (zh) | 一种将脐带间充质干细胞诱导分化成多巴胺能神经元的方法 | |
CN109234230A (zh) | 一种皮肤间充质干细胞的原代分离方法 | |
CN113583947B (zh) | 间充质干细胞和造血干细胞体外培养方法和系统 | |
CN111690686B (zh) | 一种miRNA高表达在促进脐带间充质干细胞体外增殖和成骨分化方面的应用 | |
CN104862277B (zh) | 高效离体人造血干细胞扩增培养液配方 | |
RU2645255C1 (ru) | Способ получения биобезопасной культуры мезенхимальных стволовых клеток из ворсин хориона человека | |
WO2018155952A9 (ko) | 인간 뇌 조직 유래 신경줄기세포의 고효율 분리 방법 | |
CN105624115B (zh) | 一种诱导人脐带间充质干细胞分化为神经样细胞的培养基及其诱导方法 | |
CN110484491B (zh) | 羊膜和羊水来源的内皮祖细胞获取方法及其纯化培养方法 | |
CN109722418B (zh) | 一种获取和纯化新生小鼠少突胶质前体细胞的方法 | |
WO2019221477A1 (ko) | 전구세포 배양액 및 다층 그래핀 필름을 포함하는 줄기세포 분화 촉진용 조성물 및 이의 용도 | |
CN111718898A (zh) | 提高滑膜间充质干细胞逆境耐受性的方法及其试剂 | |
CN111235093B (zh) | 一种胚胎干细胞培养基及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |